These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 32233940

  • 1. Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.
    Li N, Teeple A, Muser E, You Y, Song M, Armstrong AW.
    J Dermatolog Treat; 2022 Feb; 33(1):278-283. PubMed ID: 32233940
    [Abstract] [Full Text] [Related]

  • 2. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA.
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [Abstract] [Full Text] [Related]

  • 3. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
    Reich K, Foley P, Han C, McElligott S, Muser E, Li N, Armstrong AW.
    J Dermatolog Treat; 2020 Sep; 31(6):617-623. PubMed ID: 31305186
    [Abstract] [Full Text] [Related]

  • 4. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
    Puig L, Wu JJ, Gooderham MJ, You Y, Shen YK, Randazzo B, Kerdel F.
    J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 7. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
    Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB.
    Br J Dermatol; 2019 May; 180(5):1039-1049. PubMed ID: 30485400
    [Abstract] [Full Text] [Related]

  • 8. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K.
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
    [Abstract] [Full Text] [Related]

  • 9. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
    Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM.
    Br J Dermatol; 2021 Dec; 185(6):1146-1159. PubMed ID: 34105767
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.
    Youn SW, Yu DY, Kim TY, Kim BS, Lee SC, Lee JH, Choe YB, Lee JH, Choi JH, Roh JY, Jo SJ, Lee ES, Shin MK, Lee MG, Jiang J, Lee Y.
    J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
    [Abstract] [Full Text] [Related]

  • 11. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960
    [Abstract] [Full Text] [Related]

  • 13. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A, Muser E.
    J Med Econ; 2019 Dec 01; 22(12):1268-1273. PubMed ID: 31199173
    [Abstract] [Full Text] [Related]

  • 14. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
    Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB.
    Am J Clin Dermatol; 2020 Dec 01; 21(6):881-890. PubMed ID: 32910434
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations.
    Jo SJ, Huang YH, Tsai TF, Kim BS, Reich K, Saadoun C, Chang CL, Yang YW, Youn SW.
    J Dermatol; 2023 Sep 01; 50(9):1180-1189. PubMed ID: 37341137
    [Abstract] [Full Text] [Related]

  • 16. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis.
    Villacorta R, Teeple A, Lee S, Fakharzadeh S, Lucas J, McElligott S.
    Br J Dermatol; 2020 Sep 01; 183(3):548-558. PubMed ID: 31840228
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
    Orbai AM, Chakravarty SD, You Y, Shawi M, Yang YW, Merola JF.
    Dermatol Ther (Heidelb); 2023 Nov 01; 13(11):2859-2868. PubMed ID: 37713133
    [Abstract] [Full Text] [Related]

  • 18. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.
    N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787
    [Abstract] [Full Text] [Related]

  • 19. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
    Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, You Y, Gooderham M, Lebwohl M.
    J Eur Acad Dermatol Venereol; 2020 Aug 09; 34(8):1744-1749. PubMed ID: 32289190
    [Abstract] [Full Text] [Related]

  • 20. Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
    Yang J, Wang Z, Zhang X.
    J Immunol Res; 2020 Aug 09; 2020():4975628. PubMed ID: 32724829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.